References
- Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85–100. doi:10.1016/j.biochi.2020.09.018
- World Health Organization. WHO director-general’s opening remarks at the media briefing on COVID-19; 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020. Accessed September 8, 2022.
- World Health Organization. Weekly epidemiological update on COVID-19; 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—23-november-2021. Accessed September 8, 2022.
- World Health Organization. WHO COVID-19 dashboard. Available from: https://covid19.who.int/region/euro/country/tr. Accessed September 8, 2022.
- Su S, Du L, Jiang S. Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol. 2021;19(3):211–219. doi:10.1038/s41579-020-00462-y
- Ali I. Impact of COVID-19 on vaccination programs: adverse or positive? Hum Vaccin Immunother. 2020;16(11):2594–2600. doi:10.1080/21645515.2020.1787065
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
- Güner R, Hasanoğlu I, Aktaş F. COVID-19: prevention and control measures in community. Turk J Med Sci. 2020;50(SI–1):571–577. doi:10.3906/sag-2004-146
- Solís Arce JS, Warren SS, Meriggi NF, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021;27(8):1385–1394. doi:10.1038/s41591-021-01454-y
- Randolph HE, Barreiro LB. Herd Immunity: understanding COVID-19. Immunity. 2020;52(5):737–741. doi:10.1016/j.immuni.2020.04.012
- Massinga Loembé M, Nkengasong JN. COVID-19 vaccine access in Africa: global distribution, vaccine platforms, and challenges ahead. Immunity. 2021;54(7):1353–1362. doi:10.1016/j.immuni.2021.06.017
- Jakovljevic M, Liu Y, Cerda A, et al. The Global south political economy of health financing and spending landscape - history and presence. J Med Econ. 2021;24(sup1):25–33. doi:10.1080/13696998.2021.2007691
- Reddy KP, Fitzmaurice KP, Scott JA, et al. Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. medRxiv. 2021;2021.05.07.21256852. doi:10.1101/2021.05.07.21256852
- Pearson CAB, Bozzani F, Procter SR, et al.; CHiL COVID-19 Working Group; CMMID COVID-19 Working Group. COVID-19 vaccination in Sindh Province, Pakistan: a modelling study of health impact and cost-effectiveness. PLoS Med. 2021;18(10):e1003815. doi:10.1371/journal.pmed.1003815
- Hagens A, Inkaya AÇ, Yildirak K, et al. COVID-19 vaccination scenarios: a cost-effectiveness analysis for Turkey. Vaccines. 2021;9(4):399. doi:10.3390/vaccines9040399
- Suphanchaimat R, Tuangratananon T, Rajatanavin N, Phaiyarom M, Jaruwanno W, Uansri S. Prioritization of the target population for coronavirus disease 2019 (COVID-19) Vaccination Program in Thailand. Int J Environ Res Public Health. 2021;18(20):10803. doi:10.3390/ijerph182010803
- Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and Costing in cost-effectiveness analysis, 1974–2018. Pharmacoeconomics. 2020;38(10):1135–1145. doi:10.1007/s40273-020-00942-2
- Garrison LP Jr, Pauly MV, Willke RJ, Neumann PJ. An overview of value, perspective, and decision context-a health economics approach: an ISPOR special task force report [2]. Value Health. 2018;21(2):124–130. doi:10.1016/j.jval.2017.12.006
- Franklin M, Lomas J, Walker S, Young T. An educational review about using cost data for the purpose of cost-effectiveness analysis. Pharmacoeconomics. 2019;37(5):631–643. doi:10.1007/s40273-019-00771-y
- Supadmi W, Suwantika AA, Perwitasari DA, Abdulah R. Economic evaluations of dengue vaccination in the Southeast Asia region: evidence from a systematic review. Value Health Reg Issues. 2019;18:132–144. doi:10.1016/j.vhri.2019.02.004
- Reddy KP, Shebl FM, Foote JHA, et al. Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study. Lancet Glob Health. 2021;9(2):e120–e129. doi:10.1016/S2214-109X(20)30452-6
- Marshall DA, Grazziotin LR, Regier DA, et al. Addressing challenges of economic evaluation in precision medicine using dynamic simulation modeling. Value Health. 2020;23(5):566–573. doi:10.1016/j.jval.2020.01.016
- Ministry of Health Malaysia. Pharmacoeconomic Guidelines for Malaysia. Available from: https://www.pharmacy.gov.my/v2/sites/default/files/document-upload/pharmacoeconomic-guidelines-malaysia-malaysia-second-edition-2019-final-page-adjustment.pdf. Accessed September 8, 2022.
- Lou J, Kc S, Toh KY, et al. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. Int J Technol Assess Health Care. 2020;36(5):474–480. doi:10.1017/S0266462320000628